Search PubMed⌕ Search

Biomedical subjects

F M Muggia

Publications and source records attributed to F M Muggia.

At least 199 records · Page 11Linked to original sources
PubMed1980

The rediscovery of DON (6-diazo-5-oxo-L-norleucine).

DON (6-diazo-5-oxo-L-norleucine) and azotomycin are glutamine antagonists that were tested in human malignancies in the 1950s. Azotomycin demonstrated significant activity in colorectal cancer. DON is probably the active form of azotomycin. Recent impressive results for both of these agents in human tumor xenografts (especially the CX-2 colon tumor) have stimulated renewed clinical interest in DON, the more readily available agent. DON mechanism of action, clinical pharmacology, previous clinical data, and current phase I studies are discussed.

Animals↗
PubMed1980

Comments on the carcinogenic, mutagenic, and teratogenic properties of anticancer drugs.

Relevance of the carcinogenic effects of anticancer agents has arisen in the context of three circumstances: (a) when patients who have a favorable outlook without treatment receive chemotherapy, (b) when several alternate therapies with varying carcinogenic potential are available, and (c) when considering the introduction of a new drug into clinical investigation and/or clinical practice. Teratogenic effects require special attention when dealing with women in their reproductive years. Techniques to evaluate the mutagenic effects have opened up new areas of research and will be increasingly applied to the study of anticancer drugs.

Antineoplastic Agents↗
PubMed1980

Long-term sequelae of cancer chemotherapy.

Long-term sequelae of therapy of neoplastic disease have become an important topic, since many patients exposed to anticancer drugs will have prolonged survival. The advances which have been made in the treatment of pediatric malignancies, in fact, give particular relevance to a study of these complications. Moreover, clues as to the mechanism of action and molecular pharmacology of these agents may emerge from such studies. Herein we review both the specific organ dysfunction and the generalized effects which may become apparent as late consequences of chemotherapy.

Antineoplastic Agents↗
PubMed1980

Cytotoxic drug-induced pulmonary disease: update 1980.

Administration of a number of cytotoxic agents has been associated with interstitial pneumonitis, alveolitis and pulmonary fibrosis. Some (bleomycin, busulfan, methotrexate) are well known to cause this problem, and others (carmustine, semustine, zinostatin, mitomycin, and chlorambucil) have only recently been recognized to do so. We review and update the available information about this form of drug toxicity. Interaction between these drugs and thoracic radiation or high oxygen fractions in inspired air has produced pneumonitis at doses lower than when the drug is used alone. Synergism between the drugs themselves when given concurrently also produces pulmonary toxicity at lower doses. With some drugs and in some patients steroids will diminish the pulmonary abnormalities, but death from hypoxia is a frequent outcome. Since early recognition of the problem and withdrawal of the injurious agent is the best treatment, physician awareness of and alertness to this toxicity and its relative risk is most important. The discovery of analogs of bleomycin with a better therapeutic index, specifically reducing pulmonary damage, is one of the goals of current cancer drug development.

Alkylating Agents↗
PubMed1980

Intraarterial chemotherapy of head and neck cancer: worth another look?

Early studies of intraarterial chemotherapy in patients with squamous carcinoma of the head and neck resulted in tumor response rates similar to those achieved with systemic chemotherapy, but which were associated with unacceptable morbidity. The results of recent clinical trials suggest that intraarterial chemotherapy can achieve higher response rates than previously reported and that the frequency of morbid complications can be reduced. A summary of the discussions which took place at a recent NCI-OSITC Workshop on Intraarterial Chemotherapy of Head and Neck Cancer is presented. New therapeutic strategies and improved treatment techniques provide the rationale for a reevaluation of intraarterial chemotherapy in patients with head and neck cancer.

Antineoplastic Agents↗
PubMed1979

m-AMSA and PALA: two new agents in cancer chemotherapy.

4'-(9-Acridinylamino)methanesulfon-m-anisidide (m-AMSA) and N-(phosphonacetyl)-L-aspartate (PALA) are two new anticancer agents that have been recently introduced into clinical investigation. This review summarizes the preclinical information that has accumulated with these compounds as well as the very preliminary data presently available from early clinical trials. This information indicates the promising potential of m-AMSA and PALA in the treatment of cancer.

Aminoacridines↗